35 results about "Muscle disorder" patented technology

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.

Provided herein are compounds of Formula (I): (I), or a pharmaceutically acceptable salt or composition thereof, which are useful in the treatment or management of diseases or disorders mediated by AAK1 activity, muscle diseases and disorders, and other conditions.

The portable controllable suspension vibrator for rehabilitation is installed on a rope of a suspension instrument and comprises a shell, a vibration motor and two vibration plates, the vibration motor is arranged in the shell, and the two vibration plates are symmetrically arranged at the two ends of the shell and extend in the length direction of the shell; the front end faces of the two vibration plates are each provided with a connecting piece, and the two connecting pieces are symmetrically arranged and detachably connected with the corresponding ropes. According to the utility model, the suspension apparatus of the rehabilitation training device is connected with the vibrating plate through the rope, the vibrating plate is vibrated through the vibrating motor, and the vibration is transmitted to a patient on the rehabilitation training device through the rope, so that the patient is subjected to vibration treatment, and the rehabilitation training device is used for assisting in treating neuromuscular diseases, relieving pain, activating muscle functions and the like. The device is externally connected to the rehabilitation training device and can be adjusted according to the requirements of a patient, the structure of an original rehabilitation training device does not need to be changed, installation is convenient, and cost is low.

The invention relates to constitutively active mutants of the transcription factor TFEB, which can mutate the lysine of one or both sites of positions 219 and 347; and / or also mutate the glutamic acid of one or both sites of positions 221 and 349, in order to eliminate the SUMOylation of the protein. By replacing these residues either from positions 219 and / or 221 and / or 347 and / or 349 by any other amino acid (such as arginine or alanine), it gives rise to a mutated TFEB, which more actively induces the expression of genes and protein synthesis of the lysosomal and autophagic pathway. Such as lysosomal storage disorders, neurodegenerative diseases, liver diseases, muscle diseases and metabolic diseases, and / or disorders or processes in the aging of the skin.

The invention belongs to the technical field of biology, and discloses an application of sodium crotonate in the aspect of regulating and controlling muscle development, and an application of sodium crotonate in serving as and / or preparing a medicine for regulating and controlling muscle development. The invention discloses the dual effects of sodium crotonate in skeletal muscle development regulation for the first time, and provides a new potential target and a chemical intervention approach for muscle regeneration and treatment of atrophic myopathy and metabolic muscle diseases. On the other hand, the sodium crotonate is a low-toxicity metabolite, can be used in conventional solution preparation and injection modes, and has application prospects.

The present disclosure generally relates to the treatment of subjects having muscle disorder or at risk of developing muscle disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and / or a Folliculin (FLCN) inhibitor to the subject.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

Disclosed herein are compositions that are useful for targeting a signaling pathway modulator to a muscle cell. In some instances, such compositions may be useful in treating a muscle disorder, such as muscular dystrophy.

The present invention relates to a phytochemical-containing albumin nanocomplex and a composition containing the same for improving muscle diseases. More specifically, the present invention relates to a phytochemical-containing albumin nanocomplex that has the effect of suppressing muscle loss caused by oxidative stress or inflammatory responses and promoting the differentiation of myoblasts into muscle cells. The phytochemical-containing albumin nanocomplex effectively delivers phytochemicals to immune cells that induce reactive oxygen species and inflammatory responses, thereby regulating the muscle loss signaling mechanism induced by reactive oxygen species and inflammatory responses, suppressing muscle cell atrophy, and promoting differentiation. This can improve muscle loss and prevent and treat muscle atrophy. Therefore, a composition containing the phytochemical-containing albumin nanocomplex of the present invention can be provided as a composition for improving muscle diseases.

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

The invention discloses application of an internal ribosome entry site (IRES) element in circular RNA (Ribosome Entry Site). The IRES element can specifically drive target protein translation expression in the circular RNA in muscle cells. The invention also discloses a circular RNA (Ribosome Entry Site). The circular RNA comprises an internal ribosome Entry Site (IRES) element; the IRES element can specifically drive target protein translation expression in circular RNA in muscle cells. The invention also discloses a precursor RNA, a carrier and a pharmaceutical composition. The invention also discloses application of the circular RNA, the precursor RNA, the carrier or the pharmaceutical composition in preparation of drugs for preventing and / or treating muscle-related diseases. The IRES element can specifically drive target protein translation and high expression in circular RNA in muscle cells, different target proteins can be loaded, and a universal and efficient solution is provided for intramuscular injection of vaccines and treatment of various muscle diseases.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The present invention provides a polypeptide consisting of the sequence of SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and / or treatment of a muscle disease or disorder. The present invention also provides a nucleic acid sequence encoding the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the present invention may be administered in the form of a pharmaceutical composition, together with at least one pharmaceutically acceptable excipient, diluent, or carrier. The present invention also provides non-therapeutic methods for improving muscle function and / or increasing muscle mass in a subject.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

The present disclosure is generally directed to treating a subject having a muscle disorder or at risk of developing a muscle disorder by administering a follicin interacting protein 1 (FNIP1) inhibitor and / or a follicin (FLCN) inhibitor to the subject.

Disclosed herein are 15-hydroxyprostaglandin dehydrogenase (PGDH) inhibitor compounds. Such compounds may be administered to subjects that may benefit from prostaglandin level modulation for the treatment of muscle disorders.

Disclosed herein are inhibitors of aminocarboxymuconate semialdehyde decarboxylase (ACMSD), pharmaceutical compositions and methods for using these compounds to treat or prevent one or more ACMSD-related diseases such as, for example, muscle structure disorders, neuronal activation disorders, muscle fatigue disorders, muscle mass disorders, beta oxidation diseases, metabolic diseases, cancer, vascular diseases, ocular vascular diseases, muscular eye diseases, liver diseases, inflammatory diseases or renal diseases.

A system is provided.SOLUTION: A system for generating and displaying a facial expression for a subject whose facial expression is restricted due to a disorder of specific nerves or muscles, the system comprising: means for uploading and storing facial photograph of the subject; means for learning a AI model based on the uploaded facial photograph; means for capturing an image in real time based on an emotion selected by the subject and generating a facial expression corresponding to the emotion by the AI model; and means for displaying the generated facial expression on a tablet or AR glasses.SELECTED DRAWING: Figure 1

The present invention provides recombinant nucleic acids comprising a primary microRNA (pri-miRNA) scaffold comprising a scaffold sequence of miR-138 or miR-139 together with a guide sequence that targets a gene transcript. Methods of use of such recombinant nucleic acids for inhibiting expression of a gene or gene product are also disclosed herein.

Disclosed herein are 15-hydroxyprostaglandin dehydrogenase (PGDH) inhibitor compounds. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels for the treatment of muscle disorders.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the hematopoietic system including the hematologic system in human and veterinary medicine.

The present invention provides a method of conducting a sleep analysis by collecting physiologic and kinetic data from a subject, preferably via a wireless in-home data acquisition system, while the subject attempts to sleep at home. The sleep analysis, including clinical and research sleep studies and cardiorespiratory studies, can be used in the diagnosis of sleeping disorders and other diseases or conditions with sleep signatures, such as Parkinson's, epilepsy, chronic heart failure, chronic obstructive pulmonary disorder, or other neurological, cardiac, pulmonary, or muscular disorders. The method of the present invention can also be used to determine if environmental factors at the subject's home are preventing restorative sleep.

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

The present invention relates to an anticholinergic compound such as Darifenicin for use in the treatment of a neuromuscular disorder (in particular amyotrophic lateral sclerosis or ALS) in a human subject, wherein the neuromuscular disorder is characterized by an impaired neuromuscular transmission and / or an denervation at the NMJ (neuromuscular junction) and the anticholinergic agent is administered after symptomatic onset.

The present disclosure provides methods associated with treating chronic immune-mediated skin and muscle diseases. The present disclosure provides, inter alia, methods of treating dermatomyositis by oral administration of a JAK inhibitor or a pharmaceutically acceptable salt thereof.

Provided herein, in certain aspects, are pharmaceutical compositions comprising an HSA-IGF2 fusion protein formulated for subcutaneous administration. As provided herein, are methods of treating muscle disorders, including myotonic dystrophies, comprising administration of a pharmaceutical composition comprising an HSA-IGF2 fusion protein formulated for subcutaneous administration.